CDC-RFA-PS-24-0121: Secure Deduplication Tool for HIV Surveillance
Closed
This grant is closed. A newer notice from the same program is forecast: Demonstration Projects for Whole-Person Health Models for Women Living with HIV in the South (CDC-RFA-PS-27-0061). Status: Expected deadline March 15, 2027. It is in our archive of Centers for Disease Control - NCHHSTP notices from 2024.
Centers for Disease Control - NCHHSTP offered grants to any type of organization. It expected to make one award worth $2.4 million in total. Applications closed on May 1, 2024.
From the official notice on Grants.gov, last changed March 21, 2024. Checked November 7, 2026.
- Total funding$2.4 million
- Expected awards1
- Cost sharingNot required
- Funding typeGrant
Key dates
| Posted | March 1, 2024 |
|---|---|
| Deadline | May 1, 2024 |
| Archived by Grants.gov | May 31, 2024 |
Who can apply
This opportunity was open to any type of organization.
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Is this a realistic fit?
- Most of the program's money (97% over five years) went to state and local governments.
- No cost sharing or match is required.
What the grant funds
The purpose of this NOFO is to support a more efficient method for jurisdictions to de-duplicate cases reported to the National HIV Surveillance System. The recipient will develop and provide access to a privacy data-sharing tool that identifies potential duplicates across 59 jurisdictions; allow for secure, encrypted submission and matching of person-level HIV surveillance data; ensure data security, confidentiality, and privacy per CDC standards; recruit and negotiate with the 59 jurisdictions to participate; and provide them a report on matching levels.
Who has won HIV Prevention and Surveillance Activities-Health Department Based grants before
From fiscal 2021 to 2025, HIV Prevention and Surveillance Activities-Health Department Based (93.940) awarded $1.8 billion across 463 grant awards, an average of $3.9 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Florida Department of Health | Florida | 9 | $183 million |
| City of New York | New York | 8 | $147 million |
| California Department of Public Health | California | 7 | $119 million |
| Department of State Health Services | Texas | 7 | $92.7 million |
| County of Los Angeles | California | 9 | $88.4 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, CDC-RFA-PS-27-0061, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-PS-24-0121 still open?
No. It closed on May 1, 2024. A newer notice is forecast: CDC-RFA-PS-27-0061, expected deadline March 15, 2027.
Who can apply for Secure Deduplication Tool for HIV Surveillance?
Centers for Disease Control - NCHHSTP accepted applications from any type of organization.
What is the deadline for Secure Deduplication Tool for HIV Surveillance?
Closed May 1, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $2.4 million in total for one award.
Who has won HIV Prevention and Surveillance Activities-Health Department Based grants before?
The largest recipients over five fiscal years were Florida Department of Health, City of New York, California Department of Public Health. The program made 463 awards worth $1.8 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)